Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2017 October;65(5) > Minerva Cardioangiologica 2017 October;65(5):500-3

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

 

REVIEW  FUNCTIONAL TRICUSPID REGURGITATION: FROM PATHOPHYSIOLOGY TO THE NOVEL PERCUTANEOUS APPROACHES 

Minerva Cardioangiologica 2017 October;65(5):500-3

DOI: 10.23736/S0026-4725.17.04369-9

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

When surgery is not an option: is there a clinical need for transcatheter tricuspid valve therapies?

Alec VAHANIAN , Jean M. JULIARD, Eric BROCHET

Department of Cardiology, Hôpital Bichat, University of Paris VI, Paris, France


PDF


Severe functional tricuspid regurgitation (FTR) is frequent and carries a poor prognosis when left untreated. The strategy in symptomatic patients should be decided by a Heart Team who will choose between valve surgery, transcatheter intervention, heart transplantation or palliative medical therapy. The field of application of transcatheter tricuspid valve therapy will certainly focus on inoperable or high-risk patients first, especially those with FTR occurring late after left-sided valve surgery. If surgery is contraindicated because of multiple comorbidities interventions which are likely to be “futile” should be avoided. Conversely, if life expectancy is acceptable, it is attractive to envisage percutaneous intervention. Thus, there is a clinical need for transcatheter tricuspid valve therapies when surgery is not an option. Controlled clinical studies are necessary to show the safety profile and the performance of the new transcatheter procedures and define their potential role.


KEY WORDS: Transcatheter aortic valve replacement - Tricuspid valve - Cardiac surgical procedures

top of page